Abstract
Glucagon-like peptide-1 (GLP-1) receptor agonists target the incretin system, thereby stimulating insulin secretion. They are potent and have been proven to reduce cardiovascular events, improve renal disease progression and aid weight loss. This makes them an attractive option for patients and clinicians because many complications associated with diabetes are linked with these comorbidities. The benefits of […]
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
